摘要
目的探究健脾清肺汤联合吉非替尼对肺腺癌脾肺气虚证患者中医证候及预后的影响。方法选取2019年2月至2022年3月本院收治的140例肺腺癌患者作为研究对象,以随机数字表法将其分为对照组(70例,吉非替尼)和观察组(70例,健脾清肺汤联合吉非替尼)。比较两组的治疗效果。结果治疗后,观察组的咳嗽、痰中带血、神疲乏力、口干少饮及五心烦热评分低于对照组(P<0.05)。治疗后,观察组的CD3^(+)、CD4^(+)、自然杀伤(NK)细胞高于对照组,CD8^(+)低于对照组(P<0.05)。治疗后,观察组的糖类抗原125(CA125)、组织多肽特异性抗原(TPS)、细胞角蛋白19片段抗原(CYFRA21-1)及癌胚抗原(CEA)水平低于对照组(P<0.05)。观察组的不良反应总发生率低于对照组(P<0.05)。结论健脾清肺汤联合吉非替尼治疗肺腺癌脾肺气虚证患者的效果显著,能够改善中医证候,提高免疫功能,进而改善患者预后。
Objective To explore the effects of Jianpi Qingfei decoction combined with gefitinib on TCM syndromes and prognosis of lung adenocarcinoma patients with spleen and lung Qi deficiency syndrome.Methods A total of 140 patients with lung adenocarcinoma admitted in our hospital from February 2019 to March 2022 were selected as the research objects,and the patients were divided into control group(70 cases,gefitinib)and observation group(70 cases,Jianpi Qingfei decoction combined with gefitinib)by random number table method.The therapeutic effects of the two groups were compared.Results After treatment,the scores of cough,bloody sputum,fatigue,dry mouth and less drinking,and five upset fever in the observation group were lower than those in the control group(P<0.05).After treatment,the CD3^(+),CD4^(+) and natural killer(NK)cell in the observation group were higher than those in the control group,and CD8^(+) was lower than that in the control group(P<0.05).After treatment,the levels of carbohydrate antigen 125(CA125),tissue polypeptide specific antigen(TPS),cytokeratin 19 fragment antigen(CYFRA21-1)and carcinoembryonic antigen(CEA)in the observation group were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Jianpi Qingfei decoction combined with gefitinib has a significant effect in the treatment of lung adenocarcinoma patients with spleen and lung Qi deficiency syndrome.It can ameliorate TCM syndromes,improve immune function,and then improve the prognosis of patients.
作者
谢燕华
曹利平
苗文红
杨栓柱
XIE Yanhua;CAO Liping;MIAO Wenhong;YANG Shuanzhu(Oncology Department,Shaanxi Provincial Hospital of Chinese Medicine,Xi'an 710002,China;Cao Liping National Famous Traditional Chinese Medicine Inheritance Studio,Shaanxi Provincial Hospital of Chinese Medicine,Xi'an 710002,China;Chang'an Xie's Traditional Chinese Medicine Oncology School Inheritance Studio,Shaanxi Provincial Hospital of Chinese Medicine,Xi'an 710002,China;Lung Disease Department,Shaanxi Provincial Hospital of Chinese Medicine,Xi'an 710002,China)
出处
《临床医学研究与实践》
2024年第19期117-120,共4页
Clinical Research and Practice
基金
陕西省自然科学基础研究计划项目(No.2023-JC-YB-662)
曹利平全国名中医传承工作室建设项目。
关键词
肺腺癌
脾肺气虚证
健脾清肺汤
吉非替尼
lung adenocarcinoma
spleen and lung Qi deficiency syndrome
Jianpi Qingfei decoction
gefitinib
